272 related articles for article (PubMed ID: 31219562)
1. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F;
J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
Thorsted A; Kristoffersson AN; Maarbjerg SF; Schrøder H; Wang M; Brock B; Nielsen EI; Friberg LE
J Antimicrob Chemother; 2019 Oct; 74(10):2984-2993. PubMed ID: 31273375
[TBL] [Abstract][Full Text] [Related]
3. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
Maarbjerg SF; Thorsted A; Friberg LE; Nielsen EI; Wang M; Schrøder H; Albertsen BK
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1585. PubMed ID: 34796702
[TBL] [Abstract][Full Text] [Related]
4. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
[TBL] [Abstract][Full Text] [Related]
5. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
6. Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial.
Sime FB; Roberts MS; Tiong IS; Gardner JH; Lehman S; Peake SL; Hahn U; Warner MS; Roberts JA
J Antimicrob Chemother; 2015 Aug; 70(8):2369-75. PubMed ID: 25953805
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia.
Weber N; Jackson K; McWhinney B; Ungerer J; Kennedy G; Lipman J; Roberts JA
J Infect Chemother; 2019 Jul; 25(7):503-508. PubMed ID: 30879981
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?
Maarbjerg SF; Thorsted A; Kristoffersson A; Friberg LE; Nielsen EI; Wang M; Brock B; Schrøder H
Pediatr Blood Cancer; 2019 Jun; 66(6):e27654. PubMed ID: 30740885
[TBL] [Abstract][Full Text] [Related]
11. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
Cheatham SC; Fleming MR; Healy DP; Chung CE; Shea KM; Humphrey ML; Kays MB
Int J Antimicrob Agents; 2013 Jan; 41(1):52-6. PubMed ID: 23228881
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
Cojutti PG; Morandin E; Baraldo M; Pea F
Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
[TBL] [Abstract][Full Text] [Related]
14. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
Thabit AK; Grupper M; Nicolau DP; Kuti JL
J Pharm Pract; 2017 Dec; 30(6):593-599. PubMed ID: 29121839
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
Bue M; Sou T; Okkels ASL; Hanberg P; Thorsted A; Friberg LE; Andersson TL; Öbrink-Hansen K; Christensen S
Int J Infect Dis; 2020 Mar; 92():133-140. PubMed ID: 31978581
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF).
Donnellan S; Wright DFB; Roberts JA; Duffull SB; Schollum JBW; Putt TL; Wallis SC; Walker RJ
Eur J Clin Pharmacol; 2020 Feb; 76(2):239-247. PubMed ID: 31814045
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.
Thibault C; Lavigne J; Litalien C; Kassir N; Théorêt Y; Autmizguine J
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427292
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.
Kim YK; Kim HS; Park S; Kim HI; Lee SH; Lee DH
J Antimicrob Chemother; 2022 Apr; 77(5):1353-1364. PubMed ID: 35224630
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
